Optimas Capital’s Legend Biotech LEGN Stock Holding History

Optimas Capital’s Portfolio LEGN Stock Details LEGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-43,300	Closed	-$1.54M	–	37
2025 Q2	$1.54M	Buy	+43,300	New	+$1.4M	1.62%	18

Other funds holding LEGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Optimas Capital's LEGN Position: Q3 2025 in Review

Optimas Capital sold out of Legend Biotech (LEGN) in Q3 2025, closing a stake of 43,300 shares — an estimated $1.54M sold.

Optimas Capital first reported a position in LEGN in Q2 2025 and held it in 1 quarter. The position peaked at $1.54M in Q2 2025. 199 funds tracked by Wall St. Rank hold LEGN as of Q3 2025.

Optimas Capital reported no remaining Legend Biotech position as of Q3 2025 after selling out during the quarter.
Optimas Capital sold 43,300 Legend Biotech shares in Q3 2025, an estimated $1.54M.
Optimas Capital first reported a position in Legend Biotech in Q2 2025 and held it in 1 quarter.
Optimas Capital's Legend Biotech position peaked at $1.54M in Q2 2025.
199 funds tracked by Wall St. Rank held Legend Biotech as of Q3 2025.

Based on Optimas Capital's 13F filing for Q3 2025, filed 6 Nov 2025.